Online inquiry

IVTScrip™ mRNA-Anti-CD40, CP-870893(Cap 0, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ6192MR)

This product GTTS-WQ6192MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD40 gene. The antibody can be applied in Solid tumors, Adenocarcinoma research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001250.6
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 958
UniProt ID P25942
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD40, CP-870893(Cap 0, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ6192MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ3427MR IVTScrip™ mRNA-Anti-HGF, AV-299(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AV-299
GTTS-WQ4754MR IVTScrip™ mRNA-Anti-SOST, BPS-804(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BPS-804
GTTS-WQ7320MR IVTScrip™ mRNA-Anti-FGFR2, FPA-144(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA FPA-144
GTTS-WQ10893MR IVTScrip™ mRNA-Anti-IL1A, MABp1(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MABp1
GTTS-WQ9833MR IVTScrip™ mRNA-Anti-ICOS, JTX-2011(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA JTX-2011
GTTS-WQ12306MR IVTScrip™ mRNA-Anti-CSF2, MT203(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MT203
GTTS-WQ14780MR IVTScrip™ mRNA-Anti-CD40, SGN-40(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA SGN-40
GTTS-WQ9218MR IVTScrip™ mRNA-Anti-MS4A1, IMMU-106(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA IMMU-106
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW